Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer To Acquire Medivation in $14 Billion Deal

XTALKS VITALS NEWS

Acquisition

The winning bid is worth a staggering $81.50 per share, surprising analysts who thought that $75 would be the ceiling.

Tweetables from this article:

Tweet: Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process http://ctt.ec/xdGUu+Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process.

Tweet: Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak http://ctt.ec/6u3e7+Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak.

Share this!

August 23, 2016 | by Sarah Massey, M.Sc.

Medivation has accepted Pfizer’s $14 billion bid to acquire the company, after a months-long process involving other bidders. The company was originally approached by Sanofi whose initial bid was $9.3 billion.

The winning bid is worth a staggering $81.50 per share, surprising analysts who thought that $75 would be the ceiling. Although Sanofi was the only other company to officially confirm their interest in acquiring the biopharmaceutical company, some have speculated that Pfizer beat out a number of other contenders, including Celgene, Merck and Gilead.

“The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer,” said Ian Read, chairman and CEO of Pfizer. “The addition of Medivation will strengthen Pfizer’s Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term.



“This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value.” According to a statement released by Pfizer, the agreement is an all-cash deal.

Medivation’s blockbuster prostate cancer drug, Xtandi (Astellas), and its Phase III PARP inhibitor oncology drugs were major factors in the bidding war. The acquisition represents a significant boost for Pfizer, after its record-breaking deal with Allergan fell through earlier this year.

Last year, Medivation’s PARP inhibitor, talazoparib, was projected to bring in $200 million at its peak. Also in the company’s pipeline are the blood cancer drug, pidilizumab, currently being tested in a Phase II clinical trial, as well as a bladder cancer drug candidate, and a multiple myeloma therapy – both of which are in the early stages of development.

“We believe the combination with Pfizer is the right next step in our growth trajectory and is a testament to the passion and dedication by which the Medivation team has delivered on our mission to profoundly transform patients’ lives through medically innovative therapies,” said Dr. David Hung, founder, president and CEO of Medivation. “We believe that Pfizer is the ideal partner to extend the reach of our blockbuster Xtandi franchise and take our promising, late-stage assets – talazoparib and pidiluzimab – to their next stages of development so that they can be made available to patients as quickly as possible.”


Keywords: Acquisition, Biopharmaceutical, Pipeline


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.